A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Johnson & Johnson (J&J)

Status and phase: Terminated; Phase 2

Conditions: Osteoarthritis; Joint Pain; Arthralgia; Pain; Osteoarthritis, Knee

Treatments: Drug: Oxycodone CR (standard pain medication); Drug: Placebo; Drug: JNJ-42160443

Study type: Interventional

Funder types: Industry

Identifiers

NCT01094262

42160443-PAI2006 (Other Identifier)

CR017092

2009-016831-36 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.

Full description

This is a double-blind (neither the physician nor the patient knows the name of the assigned drug) study evaluating pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo. The study will last for about 42 weeks. Patients will receive treatment for 16 weeks. Patients who qualify for the study based on their level of pain as well as other factors will receive one of the 4 possible treatments as determined by chance. Before entering the study, patients must stop using their present pain medication. During the study, patients will answer questions about their pain, side effects, and have tests performed to monitor their physical condition. The main purpose of the study is to compare pain relief with JNJ-42160443 to that of a standard pain treatment or placebo. After the treatment period, patients can return to taking the pain medication that they used before the start of the study, and their physical condition will continue to be monitored. JNJ 42160443 10 mg/mL will be provided for use in the study. Patients will receive 1 of 4 treatments for 16 weeks (wks): lower dosage of JNJ 42160443 by subcutaneous (under the skin) (SC) injection once every 4 wks + Placebo (P) capsule orally (by mouth) (PO) 2x/day, higher dosage of JNJ 42160443 by SC injection once every 4 wks + P capsule PO 2x/day, standard pain medication capsule PO 2x/day + P by SC injection once every 4 wks, or P capsule PO 2x/day + P by SC injection once every 4 wks.

Enrollment: 196 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of osteoarthritis of the knee
• Have moderate to severe pain based on a trial questionnaire
• Must be on a stable dose of pain medication for 4 weeks before entering the trial
• Medically stable condition

Exclusion criteria

• History of joint replacement surgery in the affected joint or planned surgery involving the affected joint during the trial
• Diabetes mellitus
• Uncontrolled cardiovascular disease or hypertension
• Previous treatment with another investigational NGF inhibitor therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

196 participants in 4 patient groups, including a placebo group

JNJ-42160443 (lower dose)

Experimental group

Treatment:

Drug: JNJ-42160443

Drug: JNJ-42160443

JNJ-42160443 (higher dose)

Experimental group

Treatment:

Drug: JNJ-42160443

Drug: JNJ-42160443

Oxycodone CR (standard pain medication)

Active Comparator group

Treatment:

Drug: Oxycodone CR (standard pain medication)

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo